Protective Humoral Immunity Elicited by a Needle-Free Malaria Vaccine Comprised of a Chimeric Plasmodium falciparum Circumsporozoite Protein and a Toll-Like Receptor 5 Agonist, Flagellin
出版年份 2013 全文链接
标题
Protective Humoral Immunity Elicited by a Needle-Free Malaria Vaccine Comprised of a Chimeric Plasmodium falciparum Circumsporozoite Protein and a Toll-Like Receptor 5 Agonist, Flagellin
作者
关键词
-
出版物
INFECTION AND IMMUNITY
Volume 81, Issue 12, Pages 4350-4362
出版商
American Society for Microbiology
发表日期
2013-09-17
DOI
10.1128/iai.00263-13
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Imaging murine NALT following intranasal immunization with flagellin-modified circumsporozoite protein malaria vaccines
- (2013) A Nacer et al. Mucosal Immunology
- Evaluation of the Effectiveness and Safety of Chitosan Derivatives as Adjuvants for Intranasal Vaccines
- (2013) Takashi Kobayashi et al. VIRAL IMMUNOLOGY
- A Phase 3 Trial of RTS,S/AS01 Malaria Vaccine in African Infants
- (2012) NEW ENGLAND JOURNAL OF MEDICINE
- Sporozoite neutralizing antibodies elicited in mice and rhesus macaques immunized with a Plasmodium falciparum repeat peptide conjugated to meningococcal outer membrane protein complex
- (2012) Craig Przysiecki et al. Frontiers in Cellular and Infection Microbiology
- The Nasal Dendritic Cell-Targeting Flt3 Ligand as a Safe Adjuvant Elicits Effective Protection against Fatal Pneumococcal Pneumonia
- (2011) Kosuke Kataoka et al. INFECTION AND IMMUNITY
- Immunological mechanisms of vaccination
- (2011) Bali Pulendran et al. NATURE IMMUNOLOGY
- First Results of Phase 3 Trial of RTS,S/AS01 Malaria Vaccine in African Children
- (2011) NEW ENGLAND JOURNAL OF MEDICINE
- Induction of a potent immune response in the elderly using the TLR-5 agonist, flagellin, with a recombinant hemagglutinin influenza–flagellin fusion vaccine (VAX125, STF2.HA1 SI)
- (2011) David N. Taylor et al. VACCINE
- A Research Agenda to Underpin Malaria Eradication
- (2011) Pedro L. Alonso et al. PLOS MEDICINE
- TLR5 or NLRC4 is necessary and sufficient for promotion of humoral immunity by flagellin
- (2010) Matam Vijay-Kumar et al. EUROPEAN JOURNAL OF IMMUNOLOGY
- Vaccine Adjuvants: Putting Innate Immunity to Work
- (2010) Robert L. Coffman et al. IMMUNITY
- Flagellin as an Adjuvant: Cellular Mechanisms and Potential
- (2010) S. B. Mizel et al. JOURNAL OF IMMUNOLOGY
- Effectiveness of inactivated influenza vaccine in children aged 9 months to 3 years: an observational cohort study
- (2010) Santtu Heinonen et al. LANCET INFECTIOUS DISEASES
- Immunopotentiation of Trivalent Influenza Vaccine When Given with VAX102, a Recombinant Influenza M2e Vaccine Fused to the TLR5 Ligand Flagellin
- (2010) H. Keipp Talbot et al. PLoS One
- Safety and immunogenicity of a recombinant hemagglutinin influenza–flagellin fusion vaccine (VAX125) in healthy young adults
- (2010) John J. Treanor et al. VACCINE
- Direct Stimulation of tlr5+/+ CD11c+ Cells Is Necessary for the Adjuvant Activity of Flagellin
- (2009) J. T. Bates et al. JOURNAL OF IMMUNOLOGY
- Randomized, Double‐Blind, Phase 2a Trial of Falciparum Malaria Vaccines RTS,S/AS01B and RTS,S/AS02A in Malaria‐Naive Adults: Safety, Efficacy, and Immunologic Associates of Protection
- (2009) Kent E. Kester et al. JOURNAL OF INFECTIOUS DISEASES
- Randomized Controlled Trial of RTS,S/AS02D and RTS,S/AS01E Malaria Candidate Vaccines Given According to Different Schedules in Ghanaian Children
- (2009) Seth Owusu-Agyei et al. PLoS One
- Enhanced Immunogenicity of Plasmodium falciparum Peptide Vaccines Using a Topical Adjuvant Containing a Potent Synthetic Toll-Like Receptor 7 Agonist, Imiquimod
- (2008) C. Othoro et al. INFECTION AND IMMUNITY
- New malaria vaccine candidates based on the Plasmodium vivax Merozoite Surface Protein-1 and the TLR-5 agonist Salmonella Typhimurium FliC flagellin
- (2008) Daniel Y. Bargieri et al. VACCINE
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started